GenPharm's time to sell

GenPharm's time to sell

Last week's announcement that Medarex Inc. will acquire GenPharm International Inc., for up to $65 million in MEDX common stock, put an upbeat wrap on the GenPharm story.

After completing both a $57 million licensing agreement with Centocor Inc. (CNTO, Malvern, Penn.) for its HuMab mouse technology and settling its lengthy altercation with Cell Genesys Inc. (CEGE,

Read the full 605 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE